Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.

doi:10.1080/10428194.2018.1452208

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.

Leukemia & lymphoma - 1 Dec 2018

Zaja Francesco, Salvi Flavia, Rossi Maura, Sabattini Elena, Evangelista Andrea, Ciccone Giovannino, Angelucci Emanuele, Gaidano Gianluca, Zanni Manuela, Ladetto Marco, Chiappella Annalisa, Vitolo Umberto, Zinzani Pier Luigi, Califano Catello, Tucci Alessandra, Patti Caterina, Pileri Stefano A, Lenti Valentina, Piccaluga Pier Paolo, Cavallo Federica, Volpetti Stefano, Perali Giulia, Assouline Sarit, Mann Koren Kathleen, Morin Ryan, Alcaide Miguel, Bushell Kevin, Fanin Renato, Levis Alessandro

Abstract excerpt

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Resistance, Neoplasm

Share to Italy

Share to Lymphoma, Large B-Cell, Diffuse

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Thrombocytopenia

Source

Open in PubMed

Identifiers

PMID: 29616865
DOI: 10.1080/10428194.2018.1452208

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.PMID 29616865Read ↗

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.Semantic proximity Read ↗

Diffuse large B-cell lymphoma: current standard treatment and future perspectives.Semantic proximity Read ↗

Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysisSemantic proximity Read ↗

Management of Drug Resistance in Mantle Cell LymphomaSemantic proximity Read ↗

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read ↗

A53-Adapted Decitabine-Containing R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Defined by LymphGen: Preliminary Results of a Prospective Proof-of-Concept StudySemantic proximity Read ↗

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Semantic proximity Read ↗

Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 StudySemantic proximity Read ↗

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trialSemantic proximity Read ↗

Phase I study of vorinostat in combination with standard <scp>CHOP</scp> in patients with newly diagnosed peripheral T‐cell lymphomaSemantic proximity Read ↗

Comprehensive Analysis of <sup>177</sup> Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination SchemesSemantic proximity Read ↗

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.